| 6/6/2024 | CV | Market Commentary: Hertz eyes convertible sale; UGI, Granite Construction on deck; Fortuna jumps on debut
|
| 11/15/2023 | CV | Market Commentary: Helix Energy refinances convertibles via junk bonds; Halozyme rises; Spirit Air rebounds
|
| 11/15/2023 | CV | Market Commentary: Morning Commentary: Convertibles secondary gains; Halozyme active; Spirit Air rebounds
|
| 7/25/2023 | CV | Market Commentary: High-grade convertible names dominate; Uber notes better; Halozyme rises; earnings eyed
|
| 7/25/2023 | CV | Market Commentary: Morning Commentary: Granite Construction convertible notes active early; Halozyme rises
|
| 7/17/2023 | CV | Market Commentary: Biopharma names up in convertibles action; EV truck makers woeful as competition rises
|
| 1/11/2023 | CV | Market Commentary: Halozyme convertibles active on missed guidance, notes redemption; Live Nation comes in
|
| 1/11/2023 | CV | Market Commentary: Morning Commentary: Halozyme convertibles in focus on missed guidance, notes redemption
|
| 1/11/2023 | CVLM | Halozyme to redeem all 1.25% convertible notes due 2024 on March 17
|
| 8/19/2022 | BK | Halozyme repays $250 million term loan and increases revolver
|
| 8/18/2022 | CVLM | Halozyme exchanges portion of 1.25% convertible notes due 2024
|
| 8/18/2022 | BK | Halozyme will repay in full $250 million term loan due 2026
|
| 8/18/2022 | CV | Halozyme issues $720 million of six-year convertibles after greenshoe exercised in full
|
| 8/16/2022 | CV | Market Commentary: Sunnova upsizes convertible notes; Halozyme jumps on trading debut; FuboTV improves
|
| 8/16/2022 | CV | Market Commentary: Morning Commentary: Sunnova convertibles offering eyed; Halozyme jumps on debut
|
| 8/16/2022 | CV | New Issue: Halozyme prices upsized $625 million six-year convertible notes to yield 1%, up 30%
|
| 8/15/2022 | CV | Market Commentary: Sunnova on deck; Halozyme convertible offering oversubscribed; UpHealth exchanges
|
| 8/15/2022 | CV | Market Commentary: Morning Commentary: Halozyme Therapeutics convertible notes on tap; UpHealth exchanges
|
| 8/15/2022 | CV | Halozyme talks $500 million six-year convertible notes to yield 1%-1.5%, up 27.5%-32.5%
|
| 5/24/2022 | BK | Halozyme closes $600 million revolving, term loans for Antares merger
|
| 4/22/2022 | SP | New Issue: GS Finance sells $8 million basket-linked notes tied to 45 stocks
|
| 12/30/2021 | BK | Halozyme Therapeutics gets $75 million three-year secured revolver
|
| 3/1/2021 | CV | Halozyme greenshoe lifts 0.25% convertibles to $805 million
|
| 2/26/2021 | CV | Market Commentary: Spotify hits aftermarket, contracts on debut; Enphase under pressure; Halozyme active
|
| 2/25/2021 | CV | Market Commentary: Spotify exchangeables eyed; $2.1 billion of notes flood secondary on weak day for stocks
|
| 2/25/2021 | CV | Market Commentary: Morning Commentary: Spotify exchangeables eyed; $2.1 billion of paper floods secondary
|
| 2/25/2021 | CV | New Issue: Halozyme prices upsized $700 million six-year convertibles to yield 0.25%, up 50%
|
| 2/24/2021 | CV | Market Commentary: Spotify, Green Plains, Chefs’ Warehouse on tap; Halozyme, Enphase convertibles eyed
|
| 2/24/2021 | CV | Market Commentary: Morning Commentary: Halozyme, Enphase Energy convertibles eyed; Dropbox up on debut
|
| 2/23/2021 | CV | Market Commentary: Halozyme convertibles on tap; Dropbox eyed, talk tightened; MicroStrategy tanks outright
|
| 2/23/2021 | CV | Halozyme talks $500 million six-year convertible notes to yield 0.25%-0.75%, up 45%-50%
|
| 11/21/2019 | CV | Market Commentary: Overnight Liberty Media/Sirius exchangeables model cheap; Tilray adds with higher shares
|
| 11/18/2019 | CV | Halozyme greenshoe lifts 1.25% five-year convertibles to $460 million
|
| 11/15/2019 | CV | Market Commentary: Sea continues to trade actively after debut; new CyberArk, Halozyme trade some; RH jumps
|
| 11/15/2019 | CV | Market Commentary: Morning Commentary: Sea convertibles continue to trade actively in line with shares
|
| 11/14/2019 | CV | Market Commentary: CyberArk outperforms among new issues; Sea, Halozyme also rise outright and on swap
|
| 11/14/2019 | CV | New Issue: Halozyme sells $400 million 1.25% five-year convertibles, up 35%
|
| 11/13/2019 | CV | Market Commentary: j2 Global edges par in active trade; planned Sea notes look cheap at midpoint of talk
|
| 11/12/2019 | CV | Market Commentary: j2 Global deal edges fair value at midpoint of talk; Halozyme, CyberArk Software on tap
|
| 11/12/2019 | CV | Halozyme plans $400 million offering of five-year convertibles to yield 1%-1.5%, up 35%-40%
|
| 1/4/2016 | PV | New Issue: Halozyme Therapeutics secures $150 million loan to fund drug studies
|
| 2/9/2012 | CVHYPF | Halozyme files automatic shelf covering stock, debt and preferreds
|
| 1/5/2010 | CVHY | Halozyme files $100 million shelf covering stock, debt and preferreds
|
| 12/1/2008 | CV | Halozyme Therapeutics files $50 million shelf
|
| 4/24/2007 | PP | Market Commentary: Halozyme secures $32.09 million from private placement; Adaltis plans C$28 million stock offering
|
| 4/24/2007 | PP | New Issue: Halozyme secures $32.1 million from private placement of stock
|
| 2/14/2007 | PP | New Issue: Halozyme seals $20 million stock deal as part of distribution agreement
|
| 2/14/2007 | PP | Market Commentary: EXCO plans $2 billion private placement of convertible preferreds; Vion prepares to seal $60 million issue
|
| 12/11/2006 | PP | New Issue: Halozyme Therapeutics concludes $11.06 million stock sale
|
| 12/11/2006 | PP | Market Commentary: Biotech deals again dominate PIPE issuance; Langer seals $28.88 million convertible offering
|
| 9/13/2006 | BT | Halozyme completes call of second tranche of warrants
|
| 9/7/2006 | BT | Halozyme expects to complete enrollment in Infuse-Morphine trial in fourth quarter
|
| 8/9/2006 | BT | Halozyme calls second tranche of warrants from January 2004 financing
|
| 8/8/2006 | BT | Halozyme starts trial with Enhanze technology
|
| 7/12/2006 | BT | Halozyme's HTI-101 enzyme effective against lung cancer in animal model
|
| 6/2/2006 | BT | Halozyme says Enhanze effective on subcutaneous delivery of antibodies
|
| 5/23/2006 | BT | Halozyme's partner granted FDA clearance for in vitro fertilization enzyme, SynVitro Cumulase
|
| 5/4/2006 | BT | Halozyme trial shows Cumulase improves IVF fertilization rate by 22% compared to bovine extract
|
| 4/26/2006 | BT | Halozyme starts Chemophase phase 1/2a bladder cancer trial
|
| 4/4/2006 | BT | Halozyme data support enzyme-chemotherapy combination in bladder cancer
|
| 3/6/2006 | BT | Halozyme finishes trial enrollment for bladder cancer drug Chemophase
|
| 2/13/2006 | BT | Halozyme Therapeutics receives notice of allowance for second human enzyme
|
| 2/8/2006 | BT | Halozyme, Baxter study of Hylenex shows positive results
|
| 2/2/2006 | BT | Halozyme begins clinical trial of Hylenex with morphine
|
| 1/24/2006 | BT | Halozyme completes enrollment for Hylenex subcutaneous hydration trial
|
| 12/15/2005 | BT | Halozyme starts trial for subcutaneous hydration with Hylenex
|
| 12/14/2005 | PP | Market Commentary: NGAS raises $37 million in note sale; biotech deals continue to dominate PIPE offerings
|
| 12/14/2005 | BTPP | New Issue: Halozyme raises additional $1.45 million from direct placement
|
| 12/13/2005 | PP | Market Commentary: CanWest raises $22.5 million from unit deal; Halozyme to wrap $16.1 million direct offering
|
| 12/13/2005 | BTPP | New Issue: Halozyme to raise $16.1 million in direct placement of stock
|
| 12/9/2005 | BT | Baxter to market Halozyme's Hylenex in Europe
|
| 12/5/2005 | BT | Halozyme gets FDA OK for Hylenex; Baxter preps for launch
|
| 10/27/2005 | BT | Halozyme enrolling bladder cancer patients in phase I trial for Chemophase
|
| 9/13/2005 | BT | Halozyme initiated by Rodman & Renshaw at market outperform
|
| 6/10/2005 | CV | Halozyme Therapeutics files $50 million shelf
|
| 11/10/2004 | PP | Halozyme calls warrants for 2.02 million shares
|
| 10/13/2004 | PP | Market Commentary: Gastar plans for $20 million private placement financing; Halozyme places $13.9 million stock
|
| 10/13/2004 | PP | New Issue: Halozyme Therapeutics sells $13.9 million of stock in private placement
|
